reference/1132145

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1132145

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article
issn	1471-2407
issueIdentifier	1
pageRange	296-
publicationName	BMC Cancer
startingPage	296
bibliographicCitation	Minami S, Kijima T, Takahashi R, Kida H, Nakatani T, Hamaguchi M, Takeuchi Y, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I. Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. BMC Cancer. 2012 Jul 18;12():296. PMID: 22809298; PMCID: PMC3437193.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_588ca9caedb9e2a786a3d79db089a2d5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05cb6dc494e2690ff0fd6bb1c4c2e8a0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0eef61bfdc64785f8703caf64d16a2d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d847e5883226b217f14fb1255ef740d6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f4ce95153a8caa4d372ea60feae0cdd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5f54c18fbdd9a0348f3ffcd5b7a347f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c6885d18c9b0ae1c2555b88bbe64588 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c9e38e030118adb1cb8bd1eb4df2be69 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8cbcc50a5214434edab85be355f39ccf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1548b9e07a253aed43d6c038787f23ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_342dfee54d9293fd33600c147fa0d99f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0aabe1c7f736a7524333f844da657603
date	2012-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1186/1471-2407-12-296 https://pubmed.ncbi.nlm.nih.gov/22809298 https://pubmed.ncbi.nlm.nih.gov/PMC3437193
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/22020 https://portal.issn.org/resource/ISSN/1471-2407
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
discusses	http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0493669 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0227083
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10050 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aeebd1980c6662678028fc899ba441eb http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127377427 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851

Total number of triples: 48.